Successful Phase 3 results for daclizumab

Joint developers Biogen (BIIB) and AbbVie (ABBV) announce positive top-line results for a Phase 3 clinical trial comparing subcutaneous daclizumab high-yield process (DAC-HYP) to intramuscular interferon beta-1a as a treatment for relapsing-remitting multiple sclerosis (RRMS). DAC-HYP achieved its primary endpoint of a statistically significant 45% reduction in annualized relapse rate.

It also achieved statistical significance on the first secondary endpoint by demonstrating superiority compared to interferon beta-1a in reducing new or newly-enlarging T2-hyperintense lesions at week 96 by 54%. It did not achieve statistical significance in the second secondary endpoint of reducing the risk of three month disability progression as measured by EDSS.

The companies plan to work with regulators to determine the appropriate timelines for filings.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs